close
Add to watchlist
Ardea Biosciences Inc (RDEA)
Ardea Biosciences, Inc., a biotechnology company, focuses on the discovery and development of small-molecule therapeutics for the treatment of gout, human immunodeficiency virus (HIV), cancer, and inflammatory diseases in the United States. The company's lead product candidate includes RDEA594, a product for the treatment of hyperuricemia and gout. Its other products comprise RDEA806 for the treatment of patients with HIV; and RDEA427, a second-generation NNRTI for the treatment of HIV, in a human micro-dose pharmacokinetic study. Ardea Biosciences is evaluating RDEA119, a non-ATP EK inhibitor, in a Phase I/II study in combination with sorafenib and as a single agent in a Phase I study, both in advanced cancer patients. It also develops RDEA436 for the treatment of inflammation. The company is based in San Diego, California.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 19.74 |
| Volume | 109447 |
| Volume Avg | 257194 |
| 52 Week High | 29.58 |
| 52 Week Low | 13.15 |
| PE | N/A |
| PE (group average) | N/A |
| EPS Year | -3.26 |
| EPS change Q/Q | -1866.67% |
| EPS change Q/Q Yr ago | -9.26% |
| EPS change Q/Q next Q est | -39.18% |
| EPS change Y/Y | -26.77% |
| REV change Q/Q | -89.6% |
| REV change Q/Q Yr ago | -45.45% |
| EPS next Q est | -0.97 |
| EPS next Y est | -2.00 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |